Evidence map›Paper›PMID 28904184›Full record

ArticleJournal of clinical microbiology2017

Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.

Alessandro Mustazzolu, Angelo Iacobino, Federico Giannoni, Claudio Piersimoni, Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA) Group, Lanfranco Fattorini

Open access · bronzeAbstract readLetter
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Pyrazinamide susceptibility testing inFrontiers in cellular and infection microbiology · 2026
    Article
  2. Enhancing diagnostic efficiency of pyrazinamide resistance inCurrent research in microbial sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alessandro MustazzoluIstituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italy.
Angelo IacobinoIstituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italy.
Federico GiannoniIstituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italy.
Claudio PiersimoniRegional Reference Mycobacteria Laboratory, United Hospitals, Ancona, Italy.
Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA) Group
Lanfranco FattoriniIstituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italy lanfranco.fattorini@iss.it.
Istituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmidohydrolasesAntitubercular AgentsDiagnostic ErrorsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPyrazinamideTuberculosisAmidohydrolasesAntitubercular AgentsPncA protein, Mycobacterium tuberculosisPyrazinamideBactec MGIT 960false resistanceMycobacterium tuberculosispyrazinamidetuberculosis

Identifiers

PMID28904184
PMCPMC5703819
OpenAlexW2754112331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.